WO2005111077A3 - Methods for treating bone cancer pain by administering a nerve growth factor antagonist - Google Patents

Methods for treating bone cancer pain by administering a nerve growth factor antagonist Download PDF

Info

Publication number
WO2005111077A3
WO2005111077A3 PCT/US2005/011786 US2005011786W WO2005111077A3 WO 2005111077 A3 WO2005111077 A3 WO 2005111077A3 US 2005011786 W US2005011786 W US 2005011786W WO 2005111077 A3 WO2005111077 A3 WO 2005111077A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer pain
administering
growth factor
nerve growth
methods
Prior art date
Application number
PCT/US2005/011786
Other languages
French (fr)
Other versions
WO2005111077A2 (en
Inventor
David L Shelton
Patrick William Mantyh
Original Assignee
Rinat Neuroscience Corp
Univ Minnesota
David L Shelton
Patrick William Mantyh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35394727&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2005111077(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to AU2005243247A priority Critical patent/AU2005243247B2/en
Priority to MXPA06011463A priority patent/MXPA06011463A/en
Priority to EP18161002.3A priority patent/EP3372614B1/en
Priority to CA2562024A priority patent/CA2562024C/en
Priority to KR1020147030240A priority patent/KR101637908B1/en
Priority to DE602005019144T priority patent/DE602005019144D1/en
Priority to CN2005800185064A priority patent/CN101023099B/en
Priority to AT05777592T priority patent/ATE456580T1/en
Priority to KR1020127028119A priority patent/KR101504729B1/en
Priority to EP05777592A priority patent/EP1732949B1/en
Priority to JP2007507500A priority patent/JP5301152B2/en
Application filed by Rinat Neuroscience Corp, Univ Minnesota, David L Shelton, Patrick William Mantyh filed Critical Rinat Neuroscience Corp
Priority to SI200530937T priority patent/SI1732949T1/en
Priority to DK05777592.6T priority patent/DK1732949T3/en
Priority to NZ549990A priority patent/NZ549990A/en
Priority to PL05777592T priority patent/PL1732949T3/en
Priority to BRPI0508390A priority patent/BRPI0508390B8/en
Priority to EP10151672.2A priority patent/EP2206728B9/en
Publication of WO2005111077A2 publication Critical patent/WO2005111077A2/en
Publication of WO2005111077A3 publication Critical patent/WO2005111077A3/en
Priority to IL178226A priority patent/IL178226A/en
Priority to NO20065070A priority patent/NO343065B1/en
Priority to HK08101876.9A priority patent/HK1111425A1/en
Priority to IL226555A priority patent/IL226555A/en
Priority to IL250826A priority patent/IL250826B/en
Priority to NO20180735A priority patent/NO345258B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

The invention features methods and compositions for preventing or treating bone cancer pain including cancer pain associated with bone metastasis by administering an antagonist of nerve growth factor (NGF). The NGF antagonist may be an anti-NGF (such as anti-hNGF) antibody that is capable of binding hNGF.
PCT/US2005/011786 2004-04-07 2005-04-07 Methods for treating bone cancer pain by administering a nerve growth factor antagonist WO2005111077A2 (en)

Priority Applications (23)

Application Number Priority Date Filing Date Title
SI200530937T SI1732949T1 (en) 2004-04-07 2005-04-07 Methods for treating bone cancer pain by administering a nerve growth factor antagonist
DK05777592.6T DK1732949T3 (en) 2004-04-07 2005-04-07 Methods for Treating Bone Cancer Pain by Administration of a Nerve Growth Factor Antagonist
MXPA06011463A MXPA06011463A (en) 2004-04-07 2005-04-07 Methods for treating bone cancer pain by administering a nerve growth factor antagonist.
NZ549990A NZ549990A (en) 2004-04-07 2005-04-07 Methods for treating bone cancer pain by administering a nerve growth factor antagonist
KR1020147030240A KR101637908B1 (en) 2004-04-07 2005-04-07 Methods for treating bone cancer pain by administering a nerve growth factor antagonist
DE602005019144T DE602005019144D1 (en) 2004-04-07 2005-04-07 METHOD FOR TREATMENT TREATMENT IN BONE CANCER DU
CN2005800185064A CN101023099B (en) 2004-04-07 2005-04-07 Methods for treating bone cancer pain by administering a nerve growth factor antagonist
AT05777592T ATE456580T1 (en) 2004-04-07 2005-04-07 METHOD FOR PAIN TREATMENT IN BONE CANCER BY ADMINISTRATION OF A NGF ANTAGONIST
KR1020127028119A KR101504729B1 (en) 2004-04-07 2005-04-07 Pharmaceutical composotion for treating bone cancer pain by administering a nerve growth factor antagonist
EP05777592A EP1732949B1 (en) 2004-04-07 2005-04-07 Methods for treating bone cancer pain by administering a nerve growth factor antagonist
JP2007507500A JP5301152B2 (en) 2004-04-07 2005-04-07 Method for treating bone cancer pain by administering a nerve growth factor antagonist
AU2005243247A AU2005243247B2 (en) 2004-04-07 2005-04-07 Methods for treating bone cancer pain by administering a nerve growth factor antagonist
EP10151672.2A EP2206728B9 (en) 2004-04-07 2005-04-07 Methods for treating bone cancer pain by administering a nerve growth factor antagonistic antibody
EP18161002.3A EP3372614B1 (en) 2004-04-07 2005-04-07 Methods for treating bone cancer pain by administering a nerve growth factor antagonist
CA2562024A CA2562024C (en) 2004-04-07 2005-04-07 Methods for treating bone cancer pain by administering a nerve growth factor antagonist
PL05777592T PL1732949T3 (en) 2004-04-07 2005-04-07 Methods for treating bone cancer pain by administering a nerve growth factor antagonist
BRPI0508390A BRPI0508390B8 (en) 2004-04-07 2005-04-07 use of an anti-ngf antagonist antibody, as well as kit and pharmaceutical composition for the treatment of bone cancer pain
IL178226A IL178226A (en) 2004-04-07 2006-09-21 Use of an anti-nerve growth factor antibody for preparation of a medicament for treating bone cancer pain
NO20065070A NO343065B1 (en) 2004-04-07 2006-11-03 Use of a nerve growth factor (NGF) antagonist for the manufacture of a medicament for the treatment of bone cancer pain in an individual, wherein the NGF antagonist is an anti-NGF antagonist antibody, anti-NGF antagonist antibody for use in the treatment of bone cancer pain in an individual. , a kit thereof for the treatment of bone cancer pain, and a pharmaceutical composition for the treatment of bone cancer pain.
HK08101876.9A HK1111425A1 (en) 2004-04-07 2008-02-21 Methods for treating bone cancer pain by administering a nerve growth factor antagonist
IL226555A IL226555A (en) 2004-04-07 2013-05-23 Use of a nerve growth factor antagonist in the manufacture of medicaments for treating bone cancer pain
IL250826A IL250826B (en) 2004-04-07 2017-02-27 Methods for treating bone cancer pain by administering a nerve growth factor antagonist
NO20180735A NO345258B1 (en) 2004-04-07 2018-05-29 Methods for treating bone cancer pain by administering a nerve growth factor antagonist.

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US56078104P 2004-04-07 2004-04-07
US60/560,781 2004-04-07
US62065404P 2004-10-19 2004-10-19
US60/620,654 2004-10-19

Publications (2)

Publication Number Publication Date
WO2005111077A2 WO2005111077A2 (en) 2005-11-24
WO2005111077A3 true WO2005111077A3 (en) 2006-04-20

Family

ID=35394727

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/011786 WO2005111077A2 (en) 2004-04-07 2005-04-07 Methods for treating bone cancer pain by administering a nerve growth factor antagonist

Country Status (24)

Country Link
US (5) US7425329B2 (en)
EP (3) EP1732949B1 (en)
JP (3) JP5301152B2 (en)
KR (3) KR101637908B1 (en)
AT (1) ATE456580T1 (en)
AU (2) AU2005243247B2 (en)
BR (1) BRPI0508390B8 (en)
CA (1) CA2562024C (en)
DE (1) DE602005019144D1 (en)
DK (2) DK2206728T3 (en)
ES (2) ES2665758T3 (en)
HK (1) HK1111425A1 (en)
HU (1) HUE037549T2 (en)
IL (3) IL178226A (en)
MX (1) MXPA06011463A (en)
NO (2) NO343065B1 (en)
NZ (1) NZ549990A (en)
PL (2) PL2206728T3 (en)
PT (2) PT2206728T (en)
RU (1) RU2389509C2 (en)
SG (1) SG152226A1 (en)
SI (2) SI1732949T1 (en)
TW (1) TWI367101B (en)
WO (1) WO2005111077A2 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7655231B2 (en) 2003-02-19 2010-02-02 Pfizer Inc. Methods for treating pain by administering a nerve growth factor antagonist and an NSAID
US7655232B2 (en) 2002-12-24 2010-02-02 Pfizer Inc. Anti-NGF antibodies and methods using same
US8007800B2 (en) 2004-04-07 2011-08-30 Pfizer Inc. Methods for treating bone cancer pain by administering a nerve growth factor antagonist antibody
US8435523B2 (en) 2009-05-04 2013-05-07 Abbott Research B.V. Antibodies against nerve growth factor (NGF) with enhanced in vivo stability
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2448956C (en) * 2001-05-30 2017-10-03 Genentech, Inc. Anti-ngf antibodies for the treatment of various disorders
AU2003304238A1 (en) * 2002-10-08 2005-01-13 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same
UA80447C2 (en) * 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
ITRM20030601A1 (en) 2003-12-24 2005-06-25 Lay Line Genomics Spa METHOD FOR THE HUMANIZATION OF HUMANIZED ANTIBODIES AND ANTIBODIES WITH IT OBTAINED.
ITRM20050290A1 (en) 2005-06-07 2006-12-08 Lay Line Genomics Spa USE OF MOLECULES ABLE TO INHIBIT THE BOND BETWEEN NGF AND ITS TRKA RECEPTOR AS AN EXTENDED EFFECT ANALGESICS.
CA2678451A1 (en) 2007-02-20 2008-08-28 Robert A. Horlick Somatic hypermutation systems
US8309088B2 (en) 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
CN101827609B (en) 2007-08-10 2014-03-12 里珍纳龙药品有限公司 High affinity human antibodies to human nerve growth factor
BRPI0821383A2 (en) * 2007-12-20 2015-06-16 Cytos Biotechnology Ag Conjugates of ngf and uses thereof
ES2435917T3 (en) 2008-02-04 2013-12-26 Lay Line Genomics S.P.A. Anti-Trk-A antibodies and derivatives thereof
MX2011003144A (en) 2008-09-24 2011-05-19 Ribomic Inc Aptamer for ngf and use thereof.
RU2016116516A (en) 2008-12-08 2018-12-07 Мандифарма Интернэшнл Корпорейшн Лимитед COMPOSITIONS OF INHIBITORS OF TYROSINKINASE PROTEIN RECEPTORS
WO2012018486A2 (en) 2010-07-26 2012-02-09 Seventh Sense Biosystems, Inc. Rapid delivery and/or receiving of fluids
WO2010101620A2 (en) 2009-03-02 2010-09-10 Seventh Sense Biosystems, Inc. Systems and methods for creating and using suction blisters or other pooled regions of fluid within the skin
US20120277629A1 (en) 2011-04-29 2012-11-01 Seventh Sense Biosystems, Inc. Systems and methods for collection and/or manipulation of blood spots or other bodily fluids
WO2011094573A1 (en) 2010-01-28 2011-08-04 Seventh Sense Biosystems, Inc. Monitoring or feedback systems and methods
PL2551346T3 (en) 2010-03-24 2016-07-29 Ribomic Inc Aptamer for ngf and use thereof
WO2011163347A2 (en) * 2010-06-23 2011-12-29 Seventh Sense Biosystems, Inc. Sampling devices and methods involving relatively little pain
WO2012009613A1 (en) 2010-07-16 2012-01-19 Seventh Sense Biosystems, Inc. Low-pressure environment for fluid transfer devices
WO2012021801A2 (en) 2010-08-13 2012-02-16 Seventh Sense Biosystems, Inc. Systems and techniques for monitoring subjects
EP2606067B1 (en) 2010-08-19 2018-02-21 Zoetis Belgium S.A. Anti-ngf antibodies and their use
KR102236459B1 (en) * 2010-11-03 2021-04-07 에티컨, 엘엘씨 Drug-eluting self-retaining sutures and methods relating thereto
WO2012064802A1 (en) 2010-11-09 2012-05-18 Seventh Sense Biosystems, Inc. Systems and interfaces for blood sampling
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
KR20190112175A (en) 2010-12-01 2019-10-02 앨더바이오 홀딩스 엘엘씨 Anti-ngf compositions and use thereof
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US20130158468A1 (en) 2011-12-19 2013-06-20 Seventh Sense Biosystems, Inc. Delivering and/or receiving material with respect to a subject surface
EP2701600B1 (en) 2011-04-29 2016-06-08 Seventh Sense Biosystems, Inc. Delivering and/or receiving fluids
WO2012149155A1 (en) 2011-04-29 2012-11-01 Seventh Sense Biosystems, Inc. Systems and methods for collecting fluid from a subject
GB201114858D0 (en) * 2011-08-29 2011-10-12 Nvip Pty Ltd Anti-nerve growth factor antibodies and methods of using the same
MY160884A (en) * 2011-05-06 2017-03-31 Nexvet Australia Pty Ltd Anti-nerve growth factor antibodies and methods of preparing and using the same
RU2640254C2 (en) * 2011-05-06 2017-12-27 Нексвет Австралия Пти Лтд Antibodies against nerve growth factor and methods for their production and application
AU2013207346A1 (en) * 2012-01-05 2014-06-05 Beech Tree Labs, Inc. Method of treating pain by administration of Nerve Growth Factor
NZ750379A (en) 2012-01-12 2022-10-28 Auxilium Int Holdings Inc Clostridium histolyticum enzymes and methods for the use thereof
WO2013184871A1 (en) 2012-06-06 2013-12-12 Zoetis Llc Caninized anti-ngf antibodies and methods thereof
US8999992B2 (en) 2013-03-15 2015-04-07 Vm Pharma Llc Crystalline forms of tryosine kinase inhibitors and their salts
NO2699580T3 (en) 2014-01-24 2018-02-24
MA39286A (en) 2014-09-17 2016-03-24 Mundipharma International Corporation Ltd CRYSTALLINE FORMS OF TYROSINE KINASE INHIBITORS AND THEIR SALTS
RU2729825C2 (en) * 2015-05-22 2020-08-12 Астеллас Фарма Инк. New fab-fragment of human ngf antibody
PL3356390T3 (en) 2015-09-28 2021-07-05 The University Of North Carolina At Chapel Hill Methods and compositions for antibody-evading virus vectors
EP3765499A1 (en) 2018-03-12 2021-01-20 Zoetis Services LLC Anti-ngf antibodies and methods thereof
CN108623687A (en) 2018-04-17 2018-10-09 中山康方生物医药有限公司 The monoclonal antibody and its encoding gene of nerve growth factor and application
CA3157700A1 (en) 2019-10-17 2021-04-22 Stridebio, Inc. Adeno-associated viral vectors for treatment of niemann-pick disease type c
KR102259515B1 (en) 2019-11-29 2021-06-02 징검다리커뮤니케이션(주) Augmented reality system for maintenance of underground pipeline
US20230122991A1 (en) * 2020-01-24 2023-04-20 Otonomy, Inc. Growth factor formulation for condition associated with otic event
US20230158057A1 (en) * 2020-04-21 2023-05-25 Duke University Compositions and methods for the treatment of pain
WO2022232420A1 (en) * 2021-04-29 2022-11-03 Insmed Incorporated Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002096458A1 (en) * 2001-05-30 2002-12-05 Genentech, Inc. Anti-ngf antibodies for the treatment of various disorders
US20040131615A1 (en) * 2002-10-08 2004-07-08 Shelton David L. Methods for treating pain by administering a nerve growth factor antagonist and an opioid analgesic and compositions containing the same
WO2004058184A2 (en) * 2002-12-24 2004-07-15 Rinat Neuroscience Corp. Anti-ngf antibodies and methods using same

Family Cites Families (146)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
SU975016A1 (en) * 1979-12-17 1982-11-23 Московский научно-исследовательский онкологический институт им.П.А.Герцена Analgetic composition
US4485045A (en) * 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4754065A (en) * 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4786593A (en) 1985-04-16 1988-11-22 Wistar Institute Of Anatomy And Biology Diagnostic method for detection of neural crest disease
US4676980A (en) * 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4800159A (en) * 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US4777124A (en) * 1986-02-28 1988-10-11 Agfa-Gevaert, N.V. Azo dye compounds for use in a dye diffusion transfer process and photographic elements incorporating them
US6548640B1 (en) * 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IN165717B (en) 1986-08-07 1989-12-23 Battelle Memorial Institute
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
WO1989009225A1 (en) 1988-03-28 1989-10-05 The Regents Of The University Of California Nerve growth factor peptides
US4855241A (en) 1988-05-26 1989-08-08 Washington University Tumor diagnostic method
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
JP2539665B2 (en) * 1988-06-20 1996-10-02 日本臓器製薬株式会社 Neurological drug
CH676786A5 (en) * 1988-10-06 1991-03-15 Lasag Ag
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5047335A (en) * 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO1990007936A1 (en) 1989-01-23 1990-07-26 Chiron Corporation Recombinant therapies for infection and hyperproliferative disorders
US6673776B1 (en) 1989-03-21 2004-01-06 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
ES2200016T3 (en) 1989-03-21 2004-03-01 Vical Incorporated EXPRESSION OF EXECUTIVE POLINUCLEOTIDIC SEQUENCES IN A VERTEBRATE.
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
EP1001032A3 (en) 1989-08-18 2005-02-23 Chiron Corporation Recombinant retroviruses delivering vector constructs to target cells
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5656435A (en) * 1989-08-28 1997-08-12 Takeda Chemical Industries, Ltd. Antibodies to peptides having NGF-like activity, said antibodies having no substantial cross-reactivity with NGF, and use thereof
ATE160288T1 (en) 1989-08-28 1997-12-15 Takeda Chemical Industries Ltd ANTIBODIES, THEIR PRODUCTION AND USE
US5229500A (en) 1989-08-30 1993-07-20 Regeneron Pharmaceuticals, Inc. Brain derived neurotrophic factor
US5180820A (en) 1989-08-30 1993-01-19 Barde Yves Alain Brain-derived neurotrophic factor
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
ZA911974B (en) 1990-03-21 1994-08-22 Res Dev Foundation Heterovesicular liposomes
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
ES2246502T3 (en) 1990-08-29 2006-02-16 Genpharm International, Inc. TRANSGENIC NON-HUMAN ANIMALS ABLE TO PRODUCE HETEROLOGICAL ANTIBODIES.
US5625126A (en) * 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) * 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) * 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5147294A (en) * 1990-10-01 1992-09-15 Trustees Of Boston University Therapeutic method for reducing chronic pain in a living subject
FR2669336B1 (en) 1990-11-20 1993-01-22 Adir NOVEL OXAZOLO PYRIDINES DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
EP0564531B1 (en) * 1990-12-03 1998-03-25 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
US5278299A (en) * 1991-03-18 1994-01-11 Scripps Clinic And Research Foundation Method and composition for synthesizing sialylated glycosyl compounds
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
LU91067I2 (en) * 1991-06-14 2004-04-02 Genentech Inc Trastuzumab and its variants and immunochemical derivatives including immotoxins
SE510853C2 (en) * 1991-07-01 1999-06-28 Volvo Technology Transfer Ab Bipolar battery
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
WO1993003769A1 (en) 1991-08-20 1993-03-04 THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTEMENT OF HEALTH AND HUMAN SERVICES Adenovirus mediated transfer of genes to the gastrointestinal tract
CA2078539C (en) 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
WO1993006213A1 (en) 1991-09-23 1993-04-01 Medical Research Council Production of chimeric antibodies - a combinatorial approach
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
AU3144193A (en) 1991-11-21 1993-06-15 Board Of Trustees Of The Leland Stanford Junior University Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases
GB9125623D0 (en) 1991-12-02 1992-01-29 Dynal As Cell modification
US5605831A (en) 1992-01-31 1997-02-25 University Of British Columbia Human melanoma cell specific antigens and antibodies
US5719032A (en) 1992-01-31 1998-02-17 University Of British Columbia Melanoma and prostate cancer specific antibodies for immunodetection and immunotherapy
US5714350A (en) * 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
FR2688514A1 (en) 1992-03-16 1993-09-17 Centre Nat Rech Scient Defective recombinant adenoviruses expressing cytokines and antitumour drugs containing them
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
JPH07507689A (en) 1992-06-08 1995-08-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Specific tissue targeting methods and compositions
US5342942A (en) 1992-06-09 1994-08-30 Warner-Lambert Company Pyrazoloquinazolone derivatives as neurotrophic agents
JPH09507741A (en) 1992-06-10 1997-08-12 アメリカ合衆国 Vector particles resistant to inactivation by human serum
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
US6210671B1 (en) * 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
EP1024198A3 (en) 1992-12-03 2002-05-29 Genzyme Corporation Pseudo-adenoviral vectors for the gene therapy of haemophiliae
US5604260A (en) * 1992-12-11 1997-02-18 Merck Frosst Canada Inc. 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
US5981568A (en) * 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5409944A (en) 1993-03-12 1995-04-25 Merck Frosst Canada, Inc. Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase
WO1994023697A1 (en) 1993-04-22 1994-10-27 Depotech Corporation Cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use
US5459183A (en) * 1993-05-19 1995-10-17 Schuller International, Inc. Low VOC furan resins and method of reducing VOCS in furan resins
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US5436265A (en) 1993-11-12 1995-07-25 Merck Frosst Canada, Inc. 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
AU687829B2 (en) 1993-06-24 1998-03-05 Advec, Inc. Adenovirus vectors for gene therapy
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
ATE215989T1 (en) 1993-09-15 2002-04-15 Chiron Corp RECOMBINANT ALPHAVIRUS VECTOR
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
SK283703B6 (en) 1993-10-25 2003-12-02 Canji, Inc. Recombinant adenoviral vector and methods of use
CN1099868C (en) 1993-11-16 2003-01-29 斯卡法玛公司 Vesicles with controlled release of actives
EP0730646A1 (en) 1993-11-23 1996-09-11 Genentech, Inc. PROTEIN TYROSINE KINASES NAMED Rse
DE69408541T2 (en) 1993-11-23 1998-08-06 Genentech Inc KINAS RECEPTOR ACTIVATION TEST
GB9402331D0 (en) 1994-02-07 1994-03-30 Univ Mcgill Nerve growth factor structural analogs and their uses
US5877016A (en) * 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
US5844092A (en) 1994-03-18 1998-12-01 Genentech, Inc. Human TRK receptors and neurotrophic factor inhibitors
US6436908B1 (en) 1995-05-30 2002-08-20 Duke University Use of exogenous β-adrenergic receptor and β-adrenergic receptor kinase gene constructs to enhance myocardial function
JP4303315B2 (en) 1994-05-09 2009-07-29 オックスフォード バイオメディカ（ユーケー）リミテッド Non-crossing retroviral vector
US6291247B1 (en) 1994-05-11 2001-09-18 Queen's University At Kingston Methods of screening for factors that disrupt neurotrophin conformation and reduce neurotrophin biological activity
US5475995A (en) 1994-05-16 1995-12-19 Livingston; George G. Truck spare tire locking rod
GB9514160D0 (en) * 1994-07-25 1995-09-13 Zeneca Ltd Aromatic compounds
US5616601A (en) 1994-07-28 1997-04-01 Gd Searle & Co 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
US5521213A (en) 1994-08-29 1996-05-28 Merck Frosst Canada, Inc. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
US5593994A (en) 1994-09-29 1997-01-14 The Dupont Merck Pharmaceutical Company Prostaglandin synthase inhibitors
WO1996017072A2 (en) 1994-11-30 1996-06-06 Chiron Viagene, Inc. Recombinant alphavirus vectors
US5633424A (en) * 1994-12-29 1997-05-27 Graves; Clinton G. Device and methods for plasma sterilization
US5552422A (en) * 1995-01-11 1996-09-03 Merck Frosst Canada, Inc. Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents
US5510368A (en) 1995-05-22 1996-04-23 Merck Frosst Canada, Inc. N-benzyl-3-indoleacetic acids as antiinflammatory drugs
US5639780A (en) 1995-05-22 1997-06-17 Merck Frosst Canada, Inc. N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors
US5604253A (en) 1995-05-22 1997-02-18 Merck Frosst Canada, Inc. N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
WO1997015593A1 (en) 1995-10-25 1997-05-01 Queen's University At Kingston Neurotrophin antagonists
GB9525180D0 (en) 1995-12-08 1996-02-07 Univ Mcgill Design of hormone-like antibodies with agonistic and antagonistic fuctions
EP0953052B1 (en) 1996-05-06 2009-03-04 Oxford BioMedica (UK) Limited Crossless retroviral vectors
UA67725C2 (en) 1996-06-03 2004-07-15 Cephalon Inc K-252a derivatives and a method for improvement of functioning and cell survival enhancement
GB9616105D0 (en) 1996-07-31 1996-09-11 Univ Kingston TrkA binding site of NGF
RU2182195C2 (en) * 1996-10-04 2002-05-10 Е.И. Дюпон Де Немур Энд Компани Polyester-based fiber
EP0930883B1 (en) 1996-10-21 2006-01-11 Allelix Biopharmaceuticals Inc. Neurotrophin antagonists for the treatment of epilepsy, alzheimer's disease and pain
US6284794B1 (en) * 1996-11-05 2001-09-04 Head Explorer Aps Method for treating tension-type headache with inhibitors of nitric oxide and nitric oxide synthase
US5839780A (en) * 1997-01-31 1998-11-24 Cauffiel; Ford B. Cabinet and table assembly for use with seating apparatus
DE19732928C2 (en) * 1997-07-31 2000-05-18 Gruenenthal Gmbh Use of substituted imidazolidine-2,4-dione compounds as pain relievers
US6376471B1 (en) 1997-10-10 2002-04-23 Johns Hopkins University Gene delivery compositions and methods
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US6127401A (en) * 1998-06-05 2000-10-03 Cephalon, Inc. Bridged indenopyrrolocarbazoles
WO2000053211A2 (en) 1999-03-09 2000-09-14 University Of Southern California Method of promoting myocyte proliferation and myocardial tissue repair
US6468990B1 (en) 1999-05-17 2002-10-22 Queen's University At Kingston Method of inhibiting binding of nerve growth factor to p75 NTR receptor
US6492380B1 (en) * 1999-05-17 2002-12-10 Queen's University At Kingston Method of inhibiting neurotrophin-receptor binding
IT1306704B1 (en) 1999-05-26 2001-10-02 Sirs Societa Italiana Per La R MONOCLONAL ANTIBODIES AND ITS SYNTHETIC OR BIOTECHNOLOGICAL DERIVATIVES ENABLE TO ACT AS ANTAGONIST MOLECULES FOR NGF.
US6399780B1 (en) * 1999-08-20 2002-06-04 Cephalon, Inc. Isomeric fused pyrrolocarbazoles and isoindolones
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
US6548062B2 (en) 2000-02-29 2003-04-15 Cephalon, Inc. Method of treating cancer with anti-neurotrophin agents
FR2807660A1 (en) 2000-04-13 2001-10-19 Warner Lambert Co Use of a nerve growth factor antagonist for the manufacture of a medicament for the prevention or treatment of chronic visceral pain
US7022484B2 (en) * 2000-06-08 2006-04-04 Board Of Regents, The University Of Texas System Methods for treating neuropathological states and neurogenic inflammatory states and methods for identifying compounds useful therein
GB0020504D0 (en) 2000-08-18 2000-10-11 Univ Bristol Therapeutic method
US6630500B2 (en) 2000-08-25 2003-10-07 Cephalon, Inc. Selected fused pyrrolocarbazoles
EP1339680A1 (en) 2000-09-01 2003-09-03 Glaxo Group Limited Substituted oxindole derivatives as tyrosine kinase inhibitors
US20030008807A1 (en) * 2001-06-14 2003-01-09 The Regents Of The University Of California Novel signaling pathway for the production of inflammatory pain and neuropathy
WO2003022261A1 (en) * 2001-09-13 2003-03-20 Miller Kenneth E Method of alleviating pain
US20040038874A1 (en) * 2002-08-22 2004-02-26 Osemwota Omoigui Method of treatment of persistent pain
US6919426B2 (en) 2002-09-19 2005-07-19 Amgen Inc. Peptides and related molecules that modulate nerve growth factor activity
GB2393383B (en) 2002-09-24 2005-12-28 Dyson Ltd A vacuum cleaning head
AU2003284010A1 (en) 2002-10-04 2004-05-04 Rinat Neuroscience Corp. Methods for treating cardiac arrhythmia and preventing death due to cardiac arrhythmia using ngf antagonists
PL211654B1 (en) 2002-10-08 2012-06-29 Rinat Neuroscience Corp Methods for treating post-surgical pain by admisnistering a nerve growth factor antagonist and compositions containing the same
AU2003304238A1 (en) 2002-10-08 2005-01-13 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same
US20060147932A1 (en) 2003-01-18 2006-07-06 Alun Davies Methods of screening for modulators of nerve growth factor
AU2004213044A1 (en) 2003-02-19 2004-09-02 Rinat Neuroscience Corp. Methods for treating pain by administering a nerve growth factor antagonist and an NSAID and compositions containing the same
DE10313883A1 (en) 2003-03-27 2004-10-07 Basf Ag Additive mixture to improve the lubricity properties of mineral oil products
TWI382031B (en) * 2003-07-15 2013-01-11 Amgen Inc Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
JP5301152B2 (en) 2004-04-07 2013-09-25 ライナット ニューロサイエンス コーポレイション Method for treating bone cancer pain by administering a nerve growth factor antagonist
PT1846451E (en) 2005-01-24 2013-08-28 Elan Pharma Int Ltd Human antibodies against human ngf

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002096458A1 (en) * 2001-05-30 2002-12-05 Genentech, Inc. Anti-ngf antibodies for the treatment of various disorders
US20040131615A1 (en) * 2002-10-08 2004-07-08 Shelton David L. Methods for treating pain by administering a nerve growth factor antagonist and an opioid analgesic and compositions containing the same
WO2004058184A2 (en) * 2002-12-24 2004-07-15 Rinat Neuroscience Corp. Anti-ngf antibodies and methods using same

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
HALVORSON KYLE G ET AL: "A blocking antibody to nerve growth factor attenuates skeletal pain induced by prostate tumor cells growing in bone", CANCER RESEARCH, vol. 65, no. 20, October 2005 (2005-10-01), pages 9426 - 9435, XP002365572, ISSN: 0008-5472 *
HONGO J-A S ET AL: "ANTIBODY BINDING REGIONS ON HUMAN NERVE GROWTH FACTOR IDENTIFIED BY HOMOLOG- AND ALANINE-SCANNING MUTAGENESIS", HYBRIDOMA, LIEBERT, NEW YORK, NY, US, vol. 19, no. 3, 2000, pages 215 - 227, XP002951932, ISSN: 0272-457X *
JONGEN J L M ET AL: "NEUROTROPHIC FACTORS AND CANCER PAIN: THE EXPRESSION OF NGF, GDNF AND BDNF BY THE MURINE OSTEOLYTIC SARCOMA CELL LINE 2472 in vitro AND in vivo AND THEIR POTENTIAL INVOLVEMENT IN BONE CANCER PAIN.", SOCIETY FOR NEUROSCIENCE ABSTRACT VIEWER AND ITINERARY PLANNER, vol. 2002, 2002, & 32ND ANNUAL MEETING OF THE SOCIETY FOR NEUROSCIENCE; ORLANDO, FLORIDA, USA; NOVEMBER 02-07, 2002, pages Abstract No. 52.20 URL - http://sf, XP009060864 *
SEVCIK M A ET AL: "Anti-NGF therapy profoundly reduces bone cancer pain and the accompanying increase in markers of peripheral and central sensitization", PAIN, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 115, no. 1-2, May 2005 (2005-05-01), pages 128 - 141, XP004844690, ISSN: 0304-3959 *
SHELTON D L ET AL: "Neurotrophins and neurotrophin antagonists as potential therapeutics", RESTORATIVE NEUROLOGY AND NEUROSCIENCE 1995 IRELAND, vol. 8, no. 1-2, 1995, pages 99 - 100, XP009060880, ISSN: 0922-6028 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7655232B2 (en) 2002-12-24 2010-02-02 Pfizer Inc. Anti-NGF antibodies and methods using same
US8088384B2 (en) 2002-12-24 2012-01-03 Rinat Neuroscience Corp. Anti-NGF antibodies and methods using same
US7655231B2 (en) 2003-02-19 2010-02-02 Pfizer Inc. Methods for treating pain by administering a nerve growth factor antagonist and an NSAID
US8007800B2 (en) 2004-04-07 2011-08-30 Pfizer Inc. Methods for treating bone cancer pain by administering a nerve growth factor antagonist antibody
US8226951B2 (en) 2004-04-07 2012-07-24 Pfizer Inc. Methods for treating bone cancer by administering a nerve growth factor antagonist antibody
US8435523B2 (en) 2009-05-04 2013-05-07 Abbott Research B.V. Antibodies against nerve growth factor (NGF) with enhanced in vivo stability
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions

Also Published As

Publication number Publication date
EP1732949B1 (en) 2010-01-27
US8007800B2 (en) 2011-08-30
NO343065B1 (en) 2018-10-22
HUE037549T2 (en) 2018-09-28
EP2206728B1 (en) 2018-03-14
JP2008500970A (en) 2008-01-17
US20120315271A1 (en) 2012-12-13
SG152226A1 (en) 2009-05-29
ATE456580T1 (en) 2010-02-15
KR20120123621A (en) 2012-11-08
KR20060135060A (en) 2006-12-28
US20090252744A1 (en) 2009-10-08
CA2562024A1 (en) 2005-11-24
IL250826A0 (en) 2017-04-30
NZ549990A (en) 2009-08-28
IL178226A (en) 2013-07-31
US8557245B2 (en) 2013-10-15
IL178226A0 (en) 2006-12-31
HK1111425A1 (en) 2008-08-08
EP1732949A2 (en) 2006-12-20
PT1732949E (en) 2010-03-23
AU2012203200B2 (en) 2014-06-26
RU2389509C2 (en) 2010-05-20
IL250826B (en) 2018-11-29
JP5706853B2 (en) 2015-04-22
NO345258B1 (en) 2020-11-23
DE602005019144D1 (en) 2010-03-18
PL1732949T3 (en) 2010-06-30
JP2013209408A (en) 2013-10-10
US20110243961A1 (en) 2011-10-06
RU2006139073A (en) 2008-05-20
TWI367101B (en) 2012-07-01
US20080081040A1 (en) 2008-04-03
EP3372614A1 (en) 2018-09-12
NO20065070L (en) 2006-11-03
WO2005111077A2 (en) 2005-11-24
IL226555A0 (en) 2013-06-27
CA2562024C (en) 2014-05-27
DK2206728T3 (en) 2018-04-23
JP5301152B2 (en) 2013-09-25
EP3372614B1 (en) 2022-06-08
SI1732949T1 (en) 2010-05-31
ES2665758T9 (en) 2019-02-01
MXPA06011463A (en) 2007-04-25
BRPI0508390B1 (en) 2020-12-22
ES2338344T3 (en) 2010-05-06
US8226951B2 (en) 2012-07-24
KR20140133952A (en) 2014-11-20
TW200603830A (en) 2006-02-01
AU2005243247B2 (en) 2012-03-01
SI2206728T1 (en) 2018-07-31
NO20180735A1 (en) 2006-11-03
JP5692732B2 (en) 2015-04-01
JP2012229238A (en) 2012-11-22
IL226555A (en) 2017-03-30
DK1732949T3 (en) 2010-04-06
PT2206728T (en) 2018-04-17
BRPI0508390B8 (en) 2021-05-25
EP2206728A1 (en) 2010-07-14
AU2005243247A1 (en) 2005-11-24
ES2665758T3 (en) 2018-04-27
KR101504729B1 (en) 2015-03-19
PL2206728T3 (en) 2018-07-31
KR101637908B1 (en) 2016-07-11
BRPI0508390A (en) 2007-08-07
EP2206728B9 (en) 2018-10-10
US7425329B2 (en) 2008-09-16
US20050265994A1 (en) 2005-12-01
AU2012203200A1 (en) 2012-06-21

Similar Documents

Publication Publication Date Title
WO2005111077A3 (en) Methods for treating bone cancer pain by administering a nerve growth factor antagonist
WO2004032870A3 (en) Methods for treating post-surgical pain by admisnistering a nerve growth factor antagonist and compositions containing the same
WO2004073653A8 (en) Methods for treating pain by administering a nerve growth factor antagonist and an nsaid and compositions containing the same
IL244803A0 (en) Humanized anti-beta7 antibodies and uses therefore
WO2005048948A3 (en) Urea derivatives as kinase modulators
WO2005000194A3 (en) Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same
WO2006110883A3 (en) Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
WO2006024018A3 (en) Compositions for treating nociceptive pain
WO2002089738A3 (en) Proteomimetic compounds and methods
TW200513468A (en) Human anti-NGF neutralizing antibodies as selective NGF pathway inhibitors
WO2007024705A3 (en) Method of treating depression using a tnf-alpha antibody
ZA200701656B (en) Humanized anti-cment antagonists
MX349188B (en) Sns-595 and methods of using the same.
DE602005021970D1 (en) USE OF PEPTIDE COMPOUNDS FOR THE TREATMENT OF PAIN BY BONE CANCER, CHEMOTHERAPY AND NUCLEOSIDE-RELATED PAIN
WO2010048026A3 (en) Fibroblast growth factor receptor-3 (fgfr-3) inhibitors and methods of treatment
WO2005085188A3 (en) Compounds and methods for anti-tumor therapy
WO2007059341A3 (en) Pyrazolothiazole protein kinase modulators
WO2006078336A3 (en) Compositions and methods for the treatment and prevention of hyperproliferative diseases
WO2005077353A8 (en) Dichloroacetate in combination with an inotrope for cardioprotection
TW200614997A (en) Leaf juice of plectranthus amboinicus for treating cancer and/or tumor

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005243247

Country of ref document: AU

Ref document number: 549990

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 178226

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 200608177

Country of ref document: ZA

Ref document number: 2562024

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/011463

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 12006501970

Country of ref document: PH

Ref document number: 2007507500

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 06103017

Country of ref document: CO

ENP Entry into the national phase

Ref document number: 2005243247

Country of ref document: AU

Date of ref document: 20050407

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005243247

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2005777592

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 6473/DELNP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 1020067023106

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2006139073

Country of ref document: RU

Ref document number: 1200601827

Country of ref document: VN

WWE Wipo information: entry into national phase

Ref document number: 200580018506.4

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2005777592

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020067023106

Country of ref document: KR

ENP Entry into the national phase

Ref document number: PI0508390

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 226555

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 250826

Country of ref document: IL